TITLE

Evaluation and Management of Breast Pain

AUTHOR(S)
Smith, Robin L.; Pruthi, Sandhya; Fitzpatrick, Lorraine A.
PUB. DATE
March 2004
SOURCE
Mayo Clinic Proceedings;Mar2004, Vol. 79 Issue 3, p353
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Pain is one of the most common breast symptoms experienced by women. It can be severe enough to interfere with usual daily activities, but the etiology and optimal treatment remain undefined. Breast pain is typically approached according to its classification as cyclic mastalgia, noncydic mastalgia, and extramammary (nonbreast) pain. Cyclic mastalgia is breast pain that has a clear relationship to the menstrual cycle. Noncyclic mastalgia may be constant or intermittent but is not associated with the menstrual cycle and often occurs after menopause. Extramammary pain arises from the chest wall or other sources and is interpreted as having a cause within the breast. The risk of cancer in a woman presenting with breast pain as her only symptom is extremely low. After appropriate clinical evaluation, most patients with breast pain respond favorably to a combination of reassurance and nonpharmacological measures. The medications danazol, tamoxifen, and bromocriptine are effective; however, the potentially serious adverse effects of these medications limit their use to selected patients with severe, sustained breast pain. The status of other therapeutic strategies and directions for future research are discussed.
ACCESSION #
12389709

 

Related Articles

  • Accuracy of transvaginal ultrasound in diagnosing endometrial pathology in women with post-menopausal bleeding on tamoxifen. J Weaver; J M McHugo; T J Clark // British Journal of Radiology;May2005, Vol. 78 Issue 929, p394 

    The incidence of endometrial pathology is increased in women with tamoxifen-induced post-menopausal bleeding (PMB). The aim of this study was to determine the accuracy of transvaginal ultrasound (TVS) in diagnosing endometrial pathology in symptomatic women taking tamoxifen, using endometrial...

  • Tamoxifen-Induced Epigenetic Silencing of Oestrogen- Regulated Genes in Anti-Hormone Resistant Breast Cancer. Stone, Andrew; Valdés-Mora, Fatima; Gee, Julia M. W.; Farrow, Lynne; McClelland, Richard A.; Fiegl, Heidi; Dutkowski, Carol; McCloy, Rachael A.; Sutherland, Robert L.; Musgrove, Elizabeth A.; Nicholson, Robert I. // PLoS ONE;Jul2012, Vol. 7 Issue 7, p1 

    In the present study, we have taken the novel approach of using an in vitro model representative of tamoxifen-withdrawal subsequent to clinical relapse to achieve a greater understanding of the mechanisms that serve to maintain the resistantcell phenotype, independent of any agonistic impact of...

  • Inhibition of the Endogenous Volume-regulated Anion Channel (VRAC) in HEK293 Cells by Acidic Di-Aryl-Ureas. H�lix, N.; Str�baek, D.; Dahl, B. H.; Christophersen, P. // Journal of Membrane Biology;Dec2003, Vol. 196 Issue 2, p83 

    The endogenous volume-regulated anion channel (VRAC) from HEK293 cells was pharmacologically characterized using the whole-cell patch-clamp technique. Under isotonic conditions a small (1.3 nS), Ca2+-independent Cl conductance was measured. However, swelling at 75% tonicity activated a VRAC...

  • Endometrial Adenocarcinoma: Beliefs and Scepticism. Sivridis, Efthimios; Giatromanolaki, Alexandra // International Journal of Surgical Pathology;Apr2004, Vol. 12 Issue 2, p99 

    Presents an account of endometrial adenocarcinoma which challenges certain rather well-established, aspects of the disease. Frequency of endometrial adenocarcinoma; Pathogenetic types; Taxonomy; Functional; state of the postmenopausal nonneoplastic endometrium; Relation of the antiestrogenic...

  • Delivering tamoxifen within solid lipid nanoparticles. Abbasalipourkabir, Roghayeh; Salehzadeh, Aref; Abdullah, Rasedee // Pharmaceutical Technology Europe;Apr2011, Vol. 23 Issue 4, p22 

    Solid lipid nanoparticles (SLNs) have been proposed as an alternative colloidal drug-delivery system for water-soluble drugs. The aim of this study was to prepare and characterise physiochemically and biologically tamoxifen-loaded SLNs to evaluate their effectiveness as a drug-delivery system to...

  • Patterns of care in Dutch postmenopausal patients with hormone-sensitive early breast cancer participating in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial. van Nes, J. G. H.; Seynaeve, C.; Maartense, E.; Roumen, R. M. H.; de Jong, R. S.; Beex, L. V. A. M.; Meershoek-Klein Kranenbarg, W. M.; Putter, H.; Nortier, J. W. R.; van de Velde, C. J. H. // Annals of Oncology;May2010, Vol. 21 Issue 5, p974 

    Background: The Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trial investigates the efficacy and safety of adjuvant exemestane alone and in sequence after tamoxifen in postmenopausal women with hormone-sensitive early breast cancer. As there was a nationwide participation in The...

  • Intracardiac leiomyomatosis : Case report and literature review. Lo, K. W.-K.; Lau, T.-K. // Archives of Gynecology & Obstetrics;Jan2001, Vol. 264 Issue 4, p209 

    We describe a case of intracardiac leiomyomatosis originating from the uterus, growing up in the inferior vena cava, and extending into the right ventricle. She also found to have lung metastasis. As she declined for further operative intervention, Tamoxifen was given for the control of disease....

  • Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00). L Perey; R Paridaens; H Hawle; K Zaman; F Nolé; H Wildiers; M Fiche; D Dietrich; P Clément; D Köberle; A Goldhirsch; B Thürlimann // Annals of Oncology;Jan2007, Vol. 18 Issue 1, p64 

    Background: The aim of this study was to evaluate the efficacy and tolerability of fulvestrant, an estrogen receptor antagonist, in postmenopausal women with hormone-responsive tumors progressing after aromatase inhibitor (AI) treatment.Patients and methods: This is a phase II, open,...

  • Estrogen agonistic/antagonistic effects of miproxifene phosphate (TAT-59). Shibata, Jiro; Toko, Toshiyuki; Saito, Hitoshi; Fujioka, Akio; Sato, Kouji; Hashimoto, Akihiro; Wierzba, Konstanty; Yamada, Yuji // Cancer Chemotherapy & Pharmacology;Feb2000, Vol. 45 Issue 2, p133 

    Purpose: We evaluated miproxifene phosphate (TAT-59) to elucidate its efficacy in antiestrogen therapy for breast cancer patients and to assess its tissue-selective estrogenic/antiestrogenic activity. Methods: Using DP-TAT-59, a major and active metabolite of TAT-59, an in vitro cell growth...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics